Research
Hormonal
Targeting specific neural circuits in the brainstem and hypothalamus using peptide-based pharmacotherapies (e.g., GLP-1 mimics) is an effective strategy for inducing weight loss and treating obesity.
Consult a healthcare provider about GLP-1 based treatments if lifestyle changes alone are insufficient. These medications work by targeting brain circuits to reduce appetite and increase satiety, offering a biologically targeted approach to weight loss.
StrongSupportsHIGH confidence
Emerging pharmacotherapies that mimic gut peptides, such as glucagon-like peptide-1 (GLP-1), have shown that targeting specific neurons in the brainstem and hypothalamus is an effective strategy for inducing weight loss and lowering the risk of obesity-associated comorbidities.
Why this rating
Based on the summary of emerging pharmacotherapies and their demonstrated effectiveness.
Source
Brain control of energy homeostasis: Implications for anti-obesity pharmacotherapy
Valdemar Brimnes Ingemann Johansen et al. · Cell · 2025
DOI 10.1016/j.cell.2025.06.010
narrative_reviewCited 34×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a neurobiological disorder driven by genetic and environmental interactions that dysregulate brain-controlled energy homeostasis, rather than a failure of individual willpower.Strong
- Obesity results from a complex interaction between environmental factors (e.g., ultra-processed foods, reduced physical activity) and genetic susceptibility, rather than environmental factors alone.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →